ACROMEGALY
Clinical trials for ACROMEGALY explained in plain language.
Never miss a new study
Get alerted when new ACROMEGALY trials appear
Sign up with your email to follow new studies for ACROMEGALY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tame acromegaly hormone levels
Disease control TerminatedThis phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo …
Matched conditions: ACROMEGALY
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill shows promise for controlling acromegaly Long-Term
Disease control TerminatedThis study looks at the long-term safety and effectiveness of an oral medication called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. About 43 adults who finished a previous related study will take the drug and be monitored for …
Matched conditions: ACROMEGALY
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New pill could tame rare growth disorder without surgery
Disease control TerminatedThis study tests an oral drug called paltusotine in 111 adults with acromegaly, a condition causing abnormal growth due to high hormone levels. Participants are not currently on other treatments. The main goal is to see if the drug safely lowers insulin-like growth factor-1 (IGF-…
Matched conditions: ACROMEGALY
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a pill replace needles for acromegaly?
Disease control TerminatedThis study tests an oral drug called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. Participants had their disease under control with standard injections and were randomly assigned to receive either paltusotine or a placebo. The …
Matched conditions: ACROMEGALY
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New 12-Week hormone therapy studied for rare tumors
Disease control TerminatedThis early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…
Matched conditions: ACROMEGALY
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC